Comparison of intermittent theta burst stimulation and high-frequency repetitive transcranial magnetic stimulation on spinal cord injury-related neuropathic pain: a sham-controlled study - Kim JK, You JI, Son S, Suh IH, Lim JY.
OBJECTIVE: To compare the effects of intermittent theta burst stimulation (iTBS) and high-frequency repetitive transcranial magnetic stimulation (rTMS) on spinal cord injury-related neuropathic pain with sham controls, using neuropathic pain-specific evalu... (Source: SafetyLit)
Source: SafetyLit - November 22, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Pain interference and depressive symptom severity across 10 years in individuals with long-term spinal cord injury - Clark JMR, Cao Y, Krause JS.
OBJECTIVE: To examine change in pain interference and depression over a 10-year time period in individuals with long-term traumatic spinal cord injury (SCI) and to identify the extent to which changes in pain interference over time predicts change in depre... (Source: SafetyLit)
Source: SafetyLit - November 22, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

CT-guided procedure shows promise for restoring smell after long COVID
A CT-guided, minimally invasive procedure called a stellate ganglion block shows promise for restoring the sense of smell in patients with long COVID, according to research to be presented at the upcoming RSNA meeting.Parosmia, or impaired sense of smell, is a known symptom of COVID-19, and research has shown that up to 60% of patients with the disease are affected by parosmia. Most recover their sense of smell over time, but some continue to experience parosmia months or years after the initial infection, the team noted."Post-COVID parosmia is common and increasingly recognized," said study lead author, Adam Zoga, MD, of ...
Source: AuntMinnie.com Headlines - November 20, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Subspecialties Neuroradiology CT 2023 Source Type: news

CRISPR Therapy Gets U.K. Approval, the First in the World
Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. [time-brightcove not-tgx=”true”] In a statement on Thursday, the Medicines and Healthcare Regulatory Agency said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel prize in 2020. The agency approved the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over. Casgevy is made by Vertex ...
Source: TIME: Health - November 16, 2023 Category: Consumer Health News Authors: MARIA CHENG / AP Tags: Uncategorized Drugs wire Source Type: news

Herniated discs can be repaired with biologic patch one day, researchers say
New, preclinical research by Penn Medicine and others revealed how a biologic patch activated by natural motion could become a key weapon in repairing herniated discs in the back and relieving pain. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 15, 2023 Category: Consumer Health News Source Type: news

New Approaches Show Promise in Helping People With Lower-Back Pain
Often there is no clearly identifiable physical cause for low-back pain, leaving patients to veer from one ineffective treatment to another. Millions of adults struggle for years with chronic low-back pain—a disabling ailment that has no easy fix. Common causes include injury, arthritis and… (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2023 Category: Consumer Health News Source Type: news

Barclays is stuck in a ‘killing ground’
Plus, the UK’s Takeover Panel feels the dealmaking pain and an Austrian property mogul’s debts come back to bite#takeoverpanel #austrian (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2023 Category: Consumer Health News Source Type: news

'I’m a chiropractor - this is the one stretch that will cure your lower back pain’
Chiropractor Doctor Karam Khodian is the TikTok sensation who has shared the best stretch to ease lower back pain while at home. (Source: Daily Express - Health)
Source: Daily Express - Health - November 11, 2023 Category: Consumer Health News Source Type: news

The Los Angeles Pain Management Orthopedic and Sports Medicine Specialists at FullRange Spine & amp; Ortho are Recognized as a 2023 Top Patient Rated Practice
At FullRange Spine & Ortho, the team of spine and orthopedic specialists treat a wide variety of injuries and conditions. They provide advanced pain management solutions, using non-invasive, regenerative therapies to avoid the risks of surgery. LOS ANGELES, Nov. 7, 2023 /CNW/ - With a... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 7, 2023 Category: Pharmaceuticals Tags: AWD Source Type: news

Should We End Obesity?
It’s unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to change not just U.S. medicine, but U.S. culture. Ozempic has done all three. Approved in 2017 as a type 2 diabetes medication, Ozempic has largely made its name—and a fortune for its manufacturer, Novo Nordisk—as a weight-loss aid. Novo Nordisk knew early on that diabetes patients often lost weight on the drug, but even company executives couldn’t have guessed how widely it would eventually take off as both ...
Source: TIME: Health - November 7, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs feature healthscienceclimate Magazine TIME 2030 Wellbeing Source Type: news

I suffered a migraine in ballet class - it turned out to be a spinal infection that's left me paralyzed for life
Sarah Todd Hammer, now 22, from North Carolina, was eight years old when she started feeling severe pain during dance class. The next morning, she was completely paralyzed from the neck down.' (Source: the Mail online | Health)
Source: the Mail online | Health - November 3, 2023 Category: Consumer Health News Source Type: news

What to Know About Hypertrophic Cardiomyopathy in Kids
The human heart is a muscle, but it’s also a kind of complicated balloon—a balloon that fills and empties roughly 60 to 100 times every minute, and several billion times during the course of a lifetime. Among people with hypertrophic cardiomyopathy, the walls of the heart muscle are abnormally thick. This thickness can interfere with the heart’s normal filling-and-emptying operation. “If you think of a balloon made with super-thick rubber, you have to blow harder to fill it, and it’s the same with a hypertrophic heart,” says Dr. Daphne Hsu, professor of pediatrics and medicine at Ped...
Source: TIME: Health - November 2, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance healthscienceclimate Source Type: news

Minnies winners for 2023 highlight AI, innovation in radiology
Each year, the Minnies award winners reflect the current challenges, issues, and advances in radiology. And 2023 is no exception.Notably, AI was even more prevalent this year among the Minnies winners than in the past. The technology figured prominently in five Minnies categories, including Hottest Clinical Procedure. And for the first time since 2018, physician burnout did not win the Minnies award for Biggest Threat to Radiology. Workforce shortages were deemed by our Expert Panel to be the biggest threat in 2023.In addition to a few previous winners adding to their Minnies trophy collection, several of this year's winne...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Erik L. Ridley, Kate Madden Yee, Will Morton, Amerigo Allegretto, and Liz Carey Tags: Clinical News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Media News - October 31, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Investor Update - October 31, 2023 Category: Pharmaceuticals Source Type: news